| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $148,742 | 2 | 12 |
Sells | $464,312 | 15 | 88 |
| GARCIA PETER S | CHIEF FINANCIAL OFFICER | 1 | $102,338 | 0 | $0 | $102,338 |
| Hemrajani Rekha | director | 1 | $46,404 | 0 | $0 | $46,404 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER | 0 | $0 | 1 | $2,483 | $-2,483 |
| Randolph Sophia | CHIEF MEDICAL OFFICER | 0 | $0 | 2 | $22,567 | $-22,567 |
| Pinto Shelly | SVP, FINANCE AND CAO | 0 | $0 | 6 | $26,353 | $-26,353 |
| Pons Jaume | PRESIDENT & CSO | 0 | $0 | 6 | $412,909 | $-412,909 |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at ALX Oncology Holdings Inc. have bought $148,742 and sold $464,312 worth of ALX Oncology Holdings Inc. stock.
On average, over the past 5 years, insiders at ALX Oncology Holdings Inc. have bought $52.18M and sold $9.08M worth of stock each year.
Highest buying activity among insiders over the last 12 months: GARCIA PETER S (CHIEF FINANCIAL OFFICER) — $102,338. Hemrajani Rekha (director) — $46,404.
The last purchase of 30,000 shares for transaction amount of $46,404 was made by Hemrajani Rekha (director) on 2024‑12‑02.
| 2025-02-19 | Sale | Pons Jaume | PRESIDENT & CSO | 1,326 0.0025% | $1.15 | $1,525 | -50.01% | |
| 2025-02-19 | Sale | Lettmann Jason | CHIEF EXECUTIVE OFFICER | 2,159 0.004% | $1.15 | $2,483 | -50.01% | |
| 2025-02-19 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 550 0.001% | $1.15 | $633 | -50.01% | |
| 2025-01-06 | Sale | Pinto Shelly | Interim CFO | 2,221 0.0043% | $1.80 | $3,998 | -54.92% | |
| 2024-12-30 | Sale | Pons Jaume | PRESIDENT & CSO | 10,796 0.02% | $1.58 | $17,060 | -48.04% | |
| 2024-12-30 | Sale | Pinto Shelly | Interim CFO | 1,426 0.0026% | $1.58 | $2,253 | -48.04% | |
| 2024-12-02 | Hemrajani Rekha | director | 30,000 0.0532% | $1.55 | $46,404 | -36.14% | ||
| 2024-08-14 | Sale | Pons Jaume | PRESIDENT & CSO | 1,937 0.0038% | $2.58 | $4,997 | -43.41% | |
| 2024-08-14 | Sale | Randolph Sophia | CHIEF MEDICAL OFFICER | 1,365 0.0027% | $2.58 | $3,522 | -43.41% | |
| 2024-08-14 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 564 0.0011% | $2.58 | $1,455 | -43.41% | |
| 2024-07-11 | Sale | Pons Jaume | PRESIDENT & CSO | 20,000 0.0516% | $7.90 | $158,076 | -80.39% | |
| 2024-07-05 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 1,823 0.0033% | $5.50 | $10,025 | -72.29% | |
| 2024-07-01 | Sale | Pons Jaume | PRESIDENT & CSO | 10,758 0.0204% | $5.82 | $62,599 | -74.71% | |
| 2024-07-01 | Sale | Randolph Sophia | CHIEF MEDICAL OFFICER | 3,273 0.0062% | $5.82 | $19,045 | -74.71% | |
| 2024-07-01 | Sale | Pinto Shelly | SVP, FINANCE AND CAO | 1,373 0.0026% | $5.82 | $7,989 | -74.71% | |
| 2024-06-13 | GARCIA PETER S | CHIEF FINANCIAL OFFICER | 12,000 0.0229% | $8.53 | $102,338 | -81.75% | ||
| 2024-06-04 | Sale | Pons Jaume | PRESIDENT & CSO | 20,000 0.0387% | $8.43 | $168,652 | -81.36% | |
| 2024-05-13 | Sale | Randolph Sophia | CHIEF MEDICAL OFFICER | 12,000 0.0243% | $15.94 | $191,339 | -89.62% | |
| 2024-05-06 | Sale | Pons Jaume | PRESIDENT & CSO | 20,000 0.0399% | $15.92 | $318,334 | -89.54% | |
| 2024-04-16 | Sale | Pons Jaume | PRESIDENT & CSO | 50,000 0.0977% | $14.20 | $710,195 | -87.65% |
| Pons Jaume | PRESIDENT & CSO | 579388 1.0841% | $248,441.57 | 0 | 20 | |
| Randolph Sophia | CHIEF MEDICAL OFFICER | 325711 0.6094% | $139,664.88 | 0 | 15 | |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER | 170270 0.3186% | $73,011.78 | 2 | 5 | +4.84% |
| GARCIA PETER S | CHIEF FINANCIAL OFFICER | 122348 0.2289% | $52,462.82 | 2 | 8 | +90.48% |
| Pinto Shelly | SVP, FINANCE AND CAO | 87352 0.1634% | $37,456.54 | 0 | 11 | |
| Hemrajani Rekha | director | 33000 0.0617% | $14,150.40 | 2 | 0 | +90.48% |
| Adelman Robert J | 5268325 9.8577% | $2.26M | 1 | 0 | +90.48% | |
| Graham G. Walmsley | director | 995000 1.8618% | $426,656.00 | 2 | 0 | +34.88% |
| GOODMAN COREY S | 850000 1.5904% | $364,480.00 | 1 | 0 | +90.48% | |
| Vivo Capital IX, LLC | 10 percent owner | 789474 1.4772% | $338,526.45 | 1 | 0 | +90.48% |
| LSV Associates, LLC | 10 percent owner | 285956 0.5351% | $122,617.93 | 1 | 4 | +90.48% |
| Pietzke Steffen | VP Fin & Chief Acct Officer | 3000 0.0056% | $1,286.40 | 1 | 0 | +90.48% |
$53,490,060 | 55 | 19.35% | $28.97M | |
$17,168,388 | 54 | -43.55% | $24.67M | |
$6,204,522 | 45 | 1.91% | $25.07M | |
$23,895,365 | 34 | -37.28% | $23.36M | |
$1,995,470 | 22 | 14.01% | $20.11M | |
$17,594,514 | 16 | -20.37% | $28.75M | |
$139,007,129 | 16 | 47.16% | $26.94M | |
$79,536,861 | 15 | -6.81% | $22.88M | |
$11,247,055 | 15 | -26.49% | $20.97M | |
$25,487,383 | 15 | -4.37% | $22.18M | |
ALX Oncology Holdings Inc. (ALXO) | $156,381,772 | 11 | 64.80% | $22.92M |
$36,538,405 | 10 | -21.99% | $21.26M | |
$5,574,954 | 8 | -0.97% | $20.61M | |
$5,045,759 | 4 | -11.33% | $25.99M | |
$1,184,658 | 4 | -22.17% | $23.52M | |
$73,632,168 | 3 | -63.24% | $22.31M | |
$245,940 | 2 | 31.12% | $20.35M | |
$30,190 | 1 | -42.39% | $21.93M | |
$500,000 | 1 | -22.94% | $25.58M |
| Increased Positions | 35 | +35.35% | 2M | +5.99% |
| Decreased Positions | 39 | -39.39% | 8M | -19.79% |
| New Positions | 9 | New | 567,027 | New |
| Sold Out Positions | 10 | Sold Out | 376,529 | Sold Out |
| Total Postitions | 95 | -4.04% | 35M | -13.8% |
| Venbio Partners Llc | $5,170.00 | 18.3% | 9.7M | 0 | 0% | 2024-12-31 |
| Redmile Group, Llc | $1,967.00 | 6.96% | 3.69M | -146,965 | -3.83% | 2024-12-31 |
| Tang Capital Management Llc | $1,757.00 | 6.22% | 3.3M | -907,852 | -21.59% | 2024-12-31 |
| Morgan Stanley | $1,332.00 | 4.72% | 2.5M | +2M | +679.09% | 2024-12-31 |
| Blackrock, Inc. | $1,233.00 | 4.37% | 2.31M | -70,447 | -2.96% | 2025-03-31 |
| Millennium Management Llc | $1,135.00 | 4.02% | 2.13M | +126,736 | +6.33% | 2024-12-31 |
| Vanguard Group Inc | $1,006.00 | 3.56% | 1.89M | +2,429 | +0.13% | 2024-12-31 |
| Fmr Llc | $987.00 | 3.49% | 1.85M | -4M | -68.43% | 2024-12-31 |
| Mpm Bioimpact Llc | $742.00 | 2.63% | 1.39M | -1M | -42.26% | 2024-12-31 |
| Almitas Capital Llc | $652.00 | 2.31% | 1.22M | +1M | New | 2024-12-31 |